Donate

Oncolink Features

Find My Cancer Drug

Cancer Types / Pediatric Cancers / Wilms' Tumor / NCI Resources

NCI CANCERLIT^® Search: Wilms' Tumor - May 2002

National Cancer Institute^®
Last Modified: May 1, 2002

Pediatric renal masses: Wilms tumor and beyond.

Collision tumor in children: a review of the literature and presentation of a rare case of mesoblastic nephroma and neuroblastoma in an infant.

Improved survival for patients with recurrent wilms tumor: the experience at St. Jude Children's Research Hospital.

Table of Contents

1
UI - 11112813
AU - Lowe LH; Isuani BH; Heller RM; Stein SM; Johnson JE; Navarro OM;
TI - Hernanz-Schulman M Pediatric renal masses: Wilms tumor and beyond.
SO - Radiographics 2000 Nov-Dec;20(6):1585-603
AD - Departments of Radiology and Radiological Sciences, Vanderbilt University Children's Hospital and Medical Center, D-1120 Medical Center North, 1211 22nd Ave S, Nashville, TN 37232, USA.
A variety of pediatric renal masses may be differentiated from Wilms tumor on the basis of their clinical and imaging features. Wilms tumor is distinguished by vascular invasion and displacement of structures and is bilateral in approximately 10% of cases. Nephroblastomatosis occurs most often in neonates and is characterized by multiple bilateral subcapsular masses, often associated with Wilms tumors. Renal cell carcinoma is unusual in children except in association with von Hippel-Lindau syndrome and typically occurs in the 2nd decade. Mesoblastic nephroma is the primary consideration in a neonate with a solid renal mass. Multilocular cystic renal tumor is suggested by a large mass with multiple cysts and little solid tissue. Clear cell sarcoma is distinguished by frequent skeletal metastases, and rhabdoid tumor is distinguished by its association with brain neoplasms. Angiomyolipoma frequently contains fat and is associated with tuberous sclerosis. Renal medullary carcinoma occurs in patients with sickle cell trait or hemoglobin SC disease and manifests as an infiltrative mass with metastases. Ossifying renal tumor of infancy is differentiated from mesoblastic nephroma by the presence of ossified elements. Metanephric adenoma lacks specific features but is always well defined. Renal lymphoma is characterized by multiple homogeneous masses, often with associated adenopathy.

2
UI - 11584425
AU - Hero B; Kremens B; Sudermann T; Haas RJ
TI - Collision tumor in children: a review of the literature and presentation of a rare case of mesoblastic nephroma and neuroblastoma in an infant.
SO - J Pediatr Surg 2001 Oct;36(10):1607-8

3
UI - 11990305
AU - Dome JS; Liu T; Krasin M; Lott L; Shearer P; Daw NC; Billups CA; Wilimas
TI - JA Improved survival for patients with recurrent wilms tumor: the experience at St. Jude Children's Research Hospital.
SO - J Pediatr Hematol Oncol 2002 Mar-Apr;24(3):192-8
AD - Department of Hematology-Oncology St. Jude Children's Research Hospital, Memphis, Tennessee 38105-2794, USA. jeff.dome@stjude.org
BACKGROUND: Reported estimates of survival for patients with recurrent Wilms tumor are 24% to 43%. Because published survival data are more than a decade old and do not reflect advances in therapy, the authors reviewed their experience in treating recurrent Wilms tumor to determine whether the probability of survival has increased. PATIENTS AND METHODS: The authors reviewed the cases of 54 patients with recurrent Wilms tumor who were treated on one of six consecutive clinical trials at St. Jude Children's Research Hospital between 1969 and 2000. RESULTS: Five-year overall survival estimates after relapse were 63.6 +/- 15.7% for patients treated during or after 1984 (n = 20) and 20.6 +/- 6.5% for patients treated before 1984 (n = 34) (P = 0.002). When the analysis was restricted to patients with high-risk clinical features, 5-year overall survival estimates were 47.6 +/- 15.7% for those treated in the modern era (n = 16) and 11.1 +/- 5.2% for those treated in the earlier era (n = 25) (P = 0.005). Only three patients received high-dose chemotherapy with autologous stem cell rescue; one survived. No patients with recurrent anaplastic histology disease survived. CONCLUSIONS: Significant progress has been achieved in the treatment of recurrent favorable-histology Wilms tumor using multimodality salvage regimens with conventional doses of chemotherapy. Novel therapeutic strategies will be necessary to cure patients with recurrent anaplastic Wilms tumor.

The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.

OncoLink I wish u knew...

Marianna provides tips for people starting cancer treatments and talks about the cancer experience. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews

Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement